Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LDX Clear all
Completed Phase 1 Interventional Results available

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

NCT01457339
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Attention & Memory Impairments in Menopausal Women

NCT01324024
View directory record Official record
Conditions
Symptomatic Menopause, Cognitive Impairments
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 6, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760889
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults

NCT00753012
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2012 · Synced Sep 6, 2026, 1:57 PM EDT
Withdrawn No phase listed Observational

Clinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)

NCT00933764
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Atlanta, Georgia • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00697515
View directory record Official record
Conditions
ADHD
Interventions
LDX, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Little Rock, Arkansas • Irvine, California • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01274221
View directory record Official record
Conditions
ADHD
Interventions
SPD489, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00807222
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Sleep
Interventions
lisdexamfetamine dimesylate
Drug
Lead sponsor
Clinical Study Centers, LLC
Other
Eligibility
6 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Sep 6, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271
View directory record Official record
Conditions
New-onset Type 1 Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

NCT01291173
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
lisdexamfetamine dimesylate (SPD489), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Little Rock, Arkansas • Beverly Hills, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

NCT01977625
View directory record Official record
Conditions
Menopause, Brain Activity, Cognition
Interventions
Lisdexamfetamine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 6, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects

NCT02659488
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AGE on the Immune System

NCT01959646
View directory record Official record
Conditions
Healthy
Interventions
Aged Garlic Extract Supplementation Group, Standard for Groups, Placebo
Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
25 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 3 Interventional

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

NCT02555150
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PRC-063, lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Effects of LDX on Functioning of College Students With ADHD

NCT01342445
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 28 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethlehem, Pennsylvania • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 6, 2026, 1:57 PM EDT
Withdrawn Phase 2 Interventional

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

NCT05035368
View directory record Official record
Conditions
Type I Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 6, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

NCT01131559
View directory record Official record
Conditions
Bipolar, Depression
Interventions
Lisdexamfetamine, Placebo control
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 6, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT02009163
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine dimesylate, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Fort Myers, Florida • Lauderhill, Florida • Leesburg, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 6, 2026, 1:57 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

NCT01017263
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
Interventions
Lis-dexamphetamine
Drug
Lead sponsor
Duke University
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Sep 6, 2026, 1:57 PM EDT